Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Jazz Pharmaceuticals Still in TroubleEben Tessari • Thu, Jun 12, 2008
To learn more about Seeking Alpha Pro, click here.
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012
-
3 Growth Mid Cap Stocks To ConsiderSupreme Alpha • Wed, Aug 22, 2012
-
Jazz Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Jazz Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptFri, Aug 8, 2008
-
Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
at CNBC.com (Jun 7, 2013)
-
at CNBC.com (May 30, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Mar 19, 2013)
-
at MarketWatch.com (Mar 12, 2013)
-
at CNBC.com (Mar 5, 2013)
-
at MarketWatch.com (Oct 2, 2012)
-
at CNBC.com (Aug 15, 2012)
-
at CNBC.com (May 22, 2012)
-
at MarketWatch.com (Feb 7, 2012)
-
at MarketWatch.com (Jan 24, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
PR Newswire (Jan 5, 2012)
-
PR Newswire (Dec 12, 2011)
-
at CNBC.com (Sep 21, 2011)
-
at CNBC.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 19, 2011)
JAZZ vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company that, since our inception, has focused on the development and commercialization of pharmaceutical products to meet important unmet medical needs in neurology and psychiatry. With our JZP-6 product candidate for the treatment of fibromyalgia, for which we... More















